H. Lundbeck A/S
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, H. Lundbeck A/S sits in the top decile of US sponsors by registered trial count (#300 of 15,742 sponsors by registered trial count).
H. Lundbeck A/S: 72 sponsored US clinical trials, 5 recruiting.
H. Lundbeck A/S sponsors 72 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 47 completed. 36 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Migraine, with 4 trials.
Top-decile sponsor footprint
H. Lundbeck A/S ranks in the top decile of sponsors by registered trial count (#300 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
47 of 63 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
72 total, page 1 of 2
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
NCT05669950
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
NCT06701526
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
A Study of Lu AF82422 in Participants With Multiple System Atrophy
NCT05104476
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
NCT06578585
A Trial Investigating Lu AF28996 in Healthy Adult Participants
NCT06277609
A Study Investigating Lu AG06474 in Healthy Young Participants
NCT05943327
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
NCT05452239
A Study Investigating Lu AG22515 in Healthy Adults
NCT05136053
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
NCT05304910
Real World Effectiveness of Eptinezumab in Participants With Migraine
NCT05284019
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
NCT05219838
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT05133323
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
NCT05081518
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines
NCT05074459
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
NCT04990219
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
NCT05064397
Vortioxetine to Prevent Return of Symptoms in Children With Depression
NCT05014919
Safety and Tolerability of Lu AG06474 in Healthy Young Men
NCT05003687
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
NCT04974359
Eptinezumab in Participants With Episodic Cluster Headache
NCT04688775
Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men
NCT04713254
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
NCT04597450
A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab
NCT04537429
Safety and Tolerability of Lu AG06479 in Healthy Young Men
NCT04473651
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
NCT04418765
Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women
NCT04405323
Lu AF28996 in Participants With Parkinson's Disease (PD)
NCT04291859
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
NCT04152083
Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease
NCT04149860
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
NCT03611569
Real-life Effectiveness of Vortioxetine in Depression
NCT03555136
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
NCT03307993
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
NCT03230864
Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women
NCT03103646
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
NCT02901587
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
NCT02871297
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
NCT02892422
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
NCT02709655
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
NCT02709746
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
NCT02717195
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
NCT02586623
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
NCT02649608
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
NCT02400346
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
NCT02187809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 8 |
| Phase 3 | 32 |
| Phase 4 | 4 |
What is open in the H. Lundbeck A/S pipeline
5 recruiting of 72 indexed (7% open); 47 completed (65%).
Phase mix: 36 late (III/IV) vs 35 early (I/II) (balanced across stages).
Top condition: Migraine (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lundbeck A/S: open-pipeline peers nationwide
Peers matched on 72 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
H. Lundbeck A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 72 trials (± recruiting share)
- Smith & Nephew · 72 trials · 4% recruiting
- University of California, Berkeley · 72 trials · 18% recruiting
- Denver Health and Hospital Authority · 73 trials · 5% recruiting
- Hugo W. Moser Research Institute at Kennedy Krieger · 73 trials · 23% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Genentech · 7% recruiting · 332 trials
- BioCryst Pharmaceuticals · 7% recruiting · 29 trials
- Wake Forest University · 7% recruiting · 100 trials
- Agios Pharmaceuticals · 7% recruiting · 44 trials
Related
What to do with this H. Lundbeck A/S page
72 registered trials is a research-attention snapshot, not an endorsement of H. Lundbeck A/S or any single study.
- 5 of H. Lundbeck A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Migraine is the condition H. Lundbeck A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Migraine trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
H. Lundbeck A/S pipeline card: 72 registered trials from official public datasets.Report a data error.